tirzepatide binge eating Weight-loss drugs could help to treat disorder GLP-1 drugs may reduce binge-eating

Fecal Calprotectin What it measures: Intestinal inflammation specifically

Wiest, D

The rationale for blending these two peptides stems from their non-overlapping receptor targets and complementary metabolic effects: Amylin Pathway (Cagrilintide): Targets amylin receptors in the brainstem Creates meal-specific satiety signals Slows gastric emptying through distinct mechanisms Reduces meal size and eating frequency Triple Agonist Pathway (Retatrutide): Activates GIP, GLP-1, and glucagon receptors Enhances insulin secretion and glucose metabolism Increases energy expenditure through glucagon effects Provides broader metabolic regulation When combined, these pathways could theoretically provide additive or synergistic effects on weight management and metabolic function

MGF works locally while IGF-1 LR3 works systemically